{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:53:46Z","timestamp":1791161626471,"version":"4.1.0"},"reference-count":74,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVES:<\/jats:title><jats:p>To evaluate the economic impact of the 2009 routine US childhood immunization schedule, including diphtheria and tetanus toxoids and acellular pertussis, Haemophilus influenzae type b conjugate, inactivated poliovirus, measles\/mumps\/rubella, hepatitis B, varicella, 7-valent pneumococcal conjugate, hepatitis A, and rotavirus vaccines; influenza vaccine was not included.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Decision analysis was conducted using population-based vaccination coverage, published vaccine efficacies, historical data on disease incidence before vaccination, and disease incidence reported during 2005 to 2009. Costs were estimated using the direct cost and societal (direct and indirect costs) perspectives. Program costs included vaccine, administration, vaccine-associated adverse events, and parent travel and work time lost. All costs were inflated to 2009 dollars, and all costs and benefits in the future were discounted at a 3% annual rate. A hypothetical 2009 US birth cohort of 4\u2009261\u2009494 infants over their lifetime was followed up from birth through death. Net present value (net savings) and benefit-cost ratios of routine childhood immunization were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Analyses showed that routine childhood immunization among members of the 2009 US birth cohort will prevent \u223c42\u2009000 early deaths and 20 million cases of disease, with net savings of $13.5 billion in direct costs and $68.8 billion in total societal costs, respectively. The direct and societal benefit-cost ratios for routine childhood vaccination with these 9 vaccines were 3.0 and 10.1.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>From both direct cost and societal perspectives, vaccinating children as recommended with these vaccines results in substantial cost savings.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2013-0698","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T03:37:56Z","timestamp":1393904276000},"page":"577-585","source":"Crossref","is-referenced-by-count":217,"title":["Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009"],"prefix":"10.1542","volume":"133","author":[{"given":"Fangjun","family":"Zhou","sequence":"first","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Shefer","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wenger","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Messonnier","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Lopez","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Moore","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy V.","family":"Murphy","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Cortese","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Rodewald","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"issue":"12","key":"2021120903192022200_B1","first-page":"241","article-title":"Ten great public health achievements\u2014United States, 1900-1999.","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"2021120903192022200_B2","first-page":"619","article-title":"Ten great public health achievements\u2014United States, 2001-2010.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120903192022200_B3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amepre.2006.03.012","article-title":"Priorities among effective clinical preventive services: results of a systematic review and analysis.","volume":"31","author":"Maciosek","year":"2006","journal-title":"Am J Prev Med"},{"issue":"12","key":"2021120903192022200_B4","first-page":"243","article-title":"Impact of vaccines universally recommended for children\u2014United States, 1990-1998.","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120903192022200_B5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"2021120903192022200_B6","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/INF.0b013e3181fefdc0","article-title":"Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data.","volume":"30","author":"Tate","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2021120903192022200_B7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpedi.159.12.1136","article-title":"Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.","volume":"159","author":"Zhou","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2021120903192022200_B8","first-page":"1","article-title":"Recommended immunization schedules for persons aged 0 through 18 years \u2013United States, 2011.","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021120903192022200_B9","first-page":"1","article-title":"Recommended immunization schedules for persons aged 0 through 18 years \u2013United States, 2009.","volume":"57","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"2021120903192022200_B10","first-page":"1171","article-title":"National, state, and local area vaccination coverage among children aged 19-35 months --- United States, 2009.","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"2021120903192022200_B11","first-page":"521","article-title":"Rotavirus vaccination coverage among infants aged 5 months - immunization information system sentinel sites, United States, June 2006-June 2009.","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"21","key":"2021120903192022200_B12","first-page":"700","article-title":"Vaccination coverage among children in kindergarten\u2014United States, 2009-10 school year.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2021120903192022200_B13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archpedi.154.8.797","article-title":"Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.","volume":"154","author":"Ekwueme","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"2021120903192022200_B14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jama.1985.03350280077024","article-title":"Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of strategy assessment.","volume":"253","author":"Cochi","year":"1985","journal-title":"JAMA"},{"issue":"4","key":"2021120903192022200_B15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1542\/peds.110.4.653","article-title":"Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis.","volume":"110","author":"Zhou","year":"2002","journal-title":"Pediatrics"},{"key":"2021120903192022200_B16","doi-asserted-by":"crossref","first-page":"s131","DOI":"10.1086\/378987","article-title":"An economic analysis of the current universal 2-dose MMR Vaccination program in the United States.","volume":"189","author":"Zhou","year":"2004","journal-title":"J Infect Dis"},{"key":"2021120903192022200_B17"},{"issue":"6","key":"2021120903192022200_B18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7883\/yoken1952.34.329","article-title":"Immunization against diphtheria in Japan.","volume":"34","author":"Murata","year":"1981","journal-title":"Jpn J Med Sci Biol"},{"issue":"4","key":"2021120903192022200_B19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00006454-198704000-00005","article-title":"Pertussis in Sweden after the cessation of general immunization in 1979.","volume":"6","author":"Romanus","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"2021120903192022200_B20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2307\/4579202","article-title":"Age incidence of the common communicable diseases in children.","volume":"44","author":"Collins","year":"1929","journal-title":"Public Health Rep"},{"issue":"1","key":"2021120903192022200_B21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/infdis\/141.1.40","article-title":"Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease.","volume":"141","author":"Granoff","year":"1980","journal-title":"J Infect Dis"},{"key":"2021120903192022200_B22","first-page":"224","article-title":"Medical importance of measles.","volume":"103","author":"Langmuir","year":"1962","journal-title":"Am J Dis Child"},{"issue":"53","key":"2021120903192022200_B23","first-page":"53","article-title":"Summary of notifiable disease, United States, 1990.","volume":"39","author":"Centers for Disease Control and Prevention","year":"1991","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021120903192022200_B24","first-page":"157","article-title":"Haemophilus influenzae vaccines","author":"Chandran","year":"2008"},{"key":"2021120903192022200_B25","first-page":"139","article-title":"Diphtheria toxoid","author":"Vitek","year":"2008"},{"key":"2021120903192022200_B26","first-page":"805","article-title":"Tetanus toxoid","author":"Wassilak","year":"2008"},{"key":"2021120903192022200_B27","first-page":"467","article-title":"Pertussis vaccine","author":"Edwards","year":"2008"},{"issue":"1","key":"2021120903192022200_B28","first-page":"1","article-title":"Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine\u2014United States, 1997-2006.","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2021120903192022200_B29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.inf.0000222403.42974.8b","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.","volume":"25","author":"Ray","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"47","key":"2021120903192022200_B30","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2009.08.045","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.","volume":"27","author":"Ray","year":"2009","journal-title":"Vaccine"},{"issue":"11","key":"2021120903192022200_B31","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.283.11.1460","article-title":"Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.","volume":"283","author":"Lieu","year":"2000","journal-title":"JAMA"},{"issue":"5","key":"2021120903192022200_B32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1542\/peds.109.5.839","article-title":"Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization.","volume":"109","author":"Armstrong","year":"2002","journal-title":"Pediatrics"},{"issue":"3","key":"2021120903192022200_B33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/infdis\/144.3.218","article-title":"A prospective study of rotavirus infection in infants and young children.","volume":"144","author":"Gurwith","year":"1981","journal-title":"J Infect Dis"},{"issue":"2","key":"2021120903192022200_B34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00006454-198702000-00006","article-title":"Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations.","volume":"6","author":"Rodriguez","year":"1987","journal-title":"Pediatr Infect Dis J"},{"issue":"17","key":"2021120903192022200_B35","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.279.17.1371","article-title":"Cost-effectiveness analysis of a rotavirus immunization program for the United States.","volume":"279","author":"Tucker","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"2021120903192022200_B36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1542\/peds.2006-2876","article-title":"Cost-effectiveness and potential impact of rotavirus vaccination in the United States.","volume":"119","author":"Widdowson","year":"2007","journal-title":"Pediatrics"},{"key":"2021120903192022200_B37","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1086\/522150","article-title":"Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005.","volume":"197","author":"Chaves","year":"2008","journal-title":"J Infect Dis"},{"issue":"15","key":"2021120903192022200_B38","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/jama.1995.03530150025029","article-title":"Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.","volume":"274","author":"Margolis","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"2021120903192022200_B39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jmv.1890440206","article-title":"Review: protective efficacy of hepatitis B vaccines in neonates.","volume":"44","author":"Andr\u00e9","year":"1994","journal-title":"J Med Virol"},{"issue":"1","key":"2021120903192022200_B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H","article-title":"Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.","volume":"60","author":"Van Herck","year":"2000","journal-title":"J Med Virol"},{"issue":"4","key":"2021120903192022200_B41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0264-410X(93)90291-5","article-title":"Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A.","volume":"11","author":"Delem","year":"1993","journal-title":"Vaccine"},{"issue":"1","key":"2021120903192022200_B42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2021120903192022200_B43","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-1021","article-title":"Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.","volume":"125","author":"Boom","year":"2010","journal-title":"Pediatrics"},{"issue":"2","key":"2021120903192022200_B44","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-3722","article-title":"Effectiveness of pentavalent rotavirus vaccine against severe disease.","volume":"128","author":"Staat","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"2021120903192022200_B45","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1542\/peds.2011-1006","article-title":"Leveraging state immunization information systems to measure the effectiveness of rotavirus vaccine.","volume":"128","author":"Cortese","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"2021120903192022200_B46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"key":"2021120903192022200_B47","unstructured":"HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.ahrq.gov\/data\/hcup\/hcupnet.htm. Accessed December 27, 2001"},{"key":"2021120903192022200_B48","volume-title":"Marketscan Database","year":"2000"},{"issue":"7","key":"2021120903192022200_B49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2105\/AJPH.75.7.739","article-title":"Benefits, risks and costs of immunization for measles, mumps and rubella.","volume":"75","author":"White","year":"1985","journal-title":"Am J Public Health"},{"key":"2021120903192022200_B50","volume-title":"A cost benefit analysis of the OPV vaccine: Report prepared for the Centers for Disease Control and Prevention.","author":"Hatziandreu","year":"1994"},{"issue":"12","key":"2021120903192022200_B51","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1996.03540120045032","article-title":"Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.","volume":"276","author":"Miller","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"2021120903192022200_B52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1542\/peds.93.3.399","article-title":"Prevalence and health impact of developmental disabilities in US children.","volume":"93","author":"Boyle","year":"1994","journal-title":"Pediatrics"},{"issue":"1","key":"2021120903192022200_B53","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2006-1573","article-title":"Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States.","volume":"119","author":"Rein","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"2021120903192022200_B54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa060775","article-title":"Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States.","volume":"355","author":"Parker","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"2021120903192022200_B55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3201\/eid1603.090198","article-title":"Effects of mumps outbreak in hospital, Chicago, Illinois, USA, 2006.","volume":"16","author":"Bonebrake","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"2021120903192022200_B56","volume-title":"Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation","author":"Haddix","year":"2003"},{"issue":"7-8","key":"2021120903192022200_B57","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0264-410X(01)00433-9","article-title":"Frequency and causes of vaccine wastage.","volume":"20","author":"Setia","year":"2002","journal-title":"Vaccine"},{"issue":"6","key":"2021120903192022200_B58","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.PHH.0000296134.70014.b0","article-title":"Childhood immunization coverage by provider type.","volume":"13","author":"Groom","year":"2007","journal-title":"J Public Health Manag Pract"},{"key":"2021120903192022200_B59","first-page":"1","article-title":"Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"45","year":"1996","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"2021120903192022200_B60","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents.","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"issue":"6","key":"2021120903192022200_B61","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.vaccine.2005.07.069","article-title":"Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS).","volume":"24","author":"DiMiceli","year":"2006","journal-title":"Vaccine"},{"issue":"14","key":"2021120903192022200_B62","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.292.14.1702","article-title":"Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine.","volume":"292","author":"Wise","year":"2004","journal-title":"JAMA"},{"issue":"15-16","key":"2021120903192022200_B63","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0264-410X(00)00396-0","article-title":"The economics of vaccinating restaurant workers against hepatitis A.","volume":"19","author":"Meltzer","year":"2001","journal-title":"Vaccine"},{"key":"2021120903192022200_B64","first-page":"1","article-title":"Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"58","author":"Cortese","year":"2009","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"2021120903192022200_B65","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2006-1572","article-title":"The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.","volume":"119","author":"Armstrong","year":"2007","journal-title":"Pediatrics"},{"issue":"34","key":"2021120903192022200_B66","first-page":"1157","article-title":"National and state vaccination coverage among children aged 19\u201335 months\u2014United States, 2010.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"2021120903192022200_B67","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsa0806477","article-title":"Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases.","volume":"360","author":"Omer","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2021120903192022200_B68","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1542\/peds.2008-2033","article-title":"Primary care physician perspectives on reimbursement for childhood immunizations.","volume":"122","author":"Freed","year":"2008","journal-title":"Pediatrics"},{"key":"2021120903192022200_B69","doi-asserted-by":"crossref","first-page":"S522","DOI":"10.1542\/peds.2009-1542L","article-title":"Role of health insurance in financing vaccinations for children and adolescents in the United States.","volume":"124","author":"Shen","year":"2009","journal-title":"Pediatrics"},{"key":"2021120903192022200_B70","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1542\/peds.2009-1542J","article-title":"Underinsurance and pediatric immunization delivery in the United States.","volume":"124","author":"Smith","year":"2009","journal-title":"Pediatrics"},{"key":"2021120903192022200_B71","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1542\/peds.2009-1542O","article-title":"Financing the delivery of vaccines to children and adolescents: challenges to the current system.","volume":"124","author":"Lindley","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"2021120903192022200_B72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOP.0b013e328341ebbf","article-title":"Reducing financial barriers to vaccinating children and adolescents in the USA.","volume":"23","author":"Bednarczyk","year":"2011","journal-title":"Curr Opin Pediatr"},{"key":"2021120903192022200_B73","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(07)60564-9","article-title":"Decline in pneumonia adminissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a comparative study.","volume":"369","author":"Grijalva","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"2021120903192022200_B74","first-page":"258","article-title":"Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/4\/577\/1099226\/peds_2013-0698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/4\/577\/1099226\/peds_2013-0698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T10:48:47Z","timestamp":1648464527000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/133\/4\/577\/32731\/Economic-Evaluation-of-the-Routine-Childhood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":74,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,1]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2013-0698","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]}}}